Photobiomodulation and alopecia: a crowdsourced survey study on patient preferences

J Cosmet Laser Ther. 2023 Nov 17;25(5-8):92-94. doi: 10.1080/14764172.2023.2284641. Epub 2023 Nov 27.

Abstract

Photobiomodulation is a treatment option for hair loss and is currently FDA cleared for androgenetic alopecia. There are a variety of photobiomodulation devices intended for at-home patient use. However, data examining user preferences is lacking. A social media-based, online survey study was completed to understand patient preferences when selecting a photobiomodulation device. Secondary outcomes examined patient experience with the device. Sixty participants responded to the 21-question survey. The majority of participants had never used a photobiomodulation device (n = 50; 86.2%). Most respondents (n = 40; 67.8%) felt the efficacy of the device was the most important aspect to consider when selecting a photobiomodulation device. Additionally, a majority of participants thought 15 (n = 22; 37.3%) or 20 minutes (n = 17; 28.8%) would be a reasonable treatment duration and would prefer a hand-free device (n = 51; 86.4%). Of the eight participants who had used a photobiomodulation device, only one was dissatisfied with the device and discontinued treatment.

Keywords: Photobiomodulation; alopecia; hair loss; low level laser therapy; patient preferences.

MeSH terms

  • Alopecia / radiotherapy
  • Crowdsourcing*
  • Humans
  • Low-Level Light Therapy* / methods
  • Patient Preference
  • Surveys and Questionnaires
  • Treatment Outcome